OmniAb, Inc. (OABI) Stock: Dividends & Earnings

Company Overview:

Market Cap: $0

Trailing PE: N/A

FWD PE: —

Payout Ratio (TTM): —

52-Week Range: $1.30 - $5.43

5 Year OABI Performance Metrics:

Total Return (with DRIP): -49.2% (-12.66% CAGR)

Total Return (no DRIP): -49.2% (-12.66% CAGR)

Share Price: -49.2% (-12.66% CAGR)

Yield on Cost (with DRIP): —

Total Invested: $10,000

Total Value (with DRIP): $5,082

Total Return $ (with DRIP): -$4,918

OABI Total Return

1M 3M 6M YTD 1Y 3Y 5Y 10Y

OABI Price Chart

1M 3M 6M YTD 1Y 3Y 5Y 10Y All

Unlock All Reports & Research Dividend Stocks like a BOSS!

Save 25% with annual plan (3 Months Free)

PRO

$171 ($14.25/mo) $102.60/yr ($8.55/mo)

7-day free trial

Unlimited Portfolio Tracker
Portfolio - Lots/Sales/Dividends
Portfolio Auto-DRIP
Buy/Sell Signals Dashboard
Stock Fundamentals
Compare Stocks Side-by-Side
Revenue & EPS Estimates
DCF Valuation Modeling

Try it free for 7 days

You save $125.40 (55%)

Projected Future Returns & Dividends for OABI

Based on past 5-year performance, here are OABI growth metrics:

Share price CAGR of -12.66%
Dividend CAGR of +0%

Using OABI CAGR metrics, we can estimate that your initial $10000 investment, over the next 10 years, should grow as follows:

	OABI (DRIP)	OABI - No DRIP
Current Price	$4.96	$4.96
Start Shares	2,016.13	2,016.13
Start Value	$10,000	$10,000

After 10 years:
Final Share Count	2,016.13	2,016.13
Dividends Payment	$0.00	$0.00
Annual Dividends	$0	$0
Yield on cost	0.00%	0.00%
Share Price	$1.28	$4.96
Total Dividends	$0	$0
Final Value	$2,583	$10,000

Estimated Future Value + Dividends - OABI

NOTE: Above numbers are our estimate based on OABI's Dividend and Price CAGR over past 5 years. These numbers should only be considered as "potential future returns"! DRIP assumes reinvesting dividends; No-DRIP assumes collecting dividends as cash.

We cannot guarantee that your actual returns will meet these estimates.

Get the best Dividend Stock Research Tools:

Save 25% with annual plan (3 Months Free)

PRO

$171 ($14.25/mo) $102.60/yr ($8.55/mo)

7-day free trial

Unlimited Portfolio Tracker
Portfolio - Lots/Sales/Dividends
Portfolio Auto-DRIP
Buy/Sell Signals Dashboard
Stock Fundamentals
Compare Stocks Side-by-Side
Revenue & EPS Estimates
DCF Valuation Modeling

Try it free for 7 days

You save $125.40 (55%)

Company Info

OmniAb, Inc. (OABI) had its IPO on , and is traded on NASDAQ stock exchange.

OmniAb, Inc. is a biotechnology company that licenses discovery research technology to pharmaceutical and biotech companies and academic institutions. OmniAb’s platform is designed to support the discovery of next-generation therapeutics by creating and screening diverse antibody repertoires, helping partners identify optimal antibodies and other target-binding proteins for drug development. Its current offerings center on proprietary transgenic animal systems and related discovery tools that enable the generation of fully human antibodies and other therapeutic candidates. The company also provides integrated and customizable solutions that combine biological and computational methods, including antigen design, immunization, high-throughput screening, and data analysis. OmniAb serves a broad range of partners across the life sciences industry, positioning itself as a technology provider in the antibody discovery and biologics research market. Headquartered in Emeryville, California, OmniAb focuses on enabling research programs rather than developing and commercializing its own drugs.

OABI website: https://www.omniab.com